Abstract：Objective: To investigate and analyse the efficacy of adjuvant chemotherapy with FOLFOX4 after surgery for stage II and III colon cancer, and to analyse the relationship between X ray repair cross complementary gene I (XRCC1), TYMS, methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and efficacy, with the aim of finding and analysing the predictors of adjuvant chemotherapy. Methods: The clinical data of 104 patients who received 6 cycles of FOLFOX4 adjuvant chemotherapy after the end of surgical treatment admitted to our hospital from May 2018 to January 2020 were retrospectively analyzed, and the 2-year disease-free survival rate was judged at follow-up after treatment and used as an efficacy evaluation criterion. DNA was extracted from tumour tissue specimens of all patients, and XRCC1, TYMS and MTHFR genotypes were tested. A chi-square test was used to compare the recurrence rates between genotypes, followed by a COX regression model to explore factors that might have an impact on the efficacy. Results: The genotype distribution of XRCC1, TYMS and MTHFR was dominated by G/A genotype, 2R/3R genotype and T/C genotype respectively, which were significantly higher than the other genotypes, and the difference was statistically significant (P<0.05). The difference was statistically significant (P<0.05). The XRCC1 gene polymorphism had a direct effect on the disease-free survival rate at 2 years after FOLFOX4 adjuvant chemotherapy for colon cancer (P<0.05). The results of the univariate analysis of the COX model showed that TNM stage, intestinal wall infiltration, XRCC1 and adjuvant chemotherapy with FOLFOX4 after surgery for colon cancer were correlated (P<0.05). Conclusion: The XRCC1 gene polymorphism has a direct correlation with disease free survival at 2 years after FOLFOX4 adjuvant chemotherapy for colon cancer.Detection of XRCC1 polymorphism can be used as a reliable predictor of the efficacy of adjuvant chemotherapy with FOLFOX4 after surgery for stage II and III colon cancer.
赵帅, 陈静, 闫海洋, 郭英, 孙静娜, 耿玉兰, 刘佳佳. XRCC1 TYMS MTHFR基因多态性与结肠癌术后辅助化疗疗效的关系[J]. 河北医学, 2022, 28(5): 750-753.
ZHAO Shuai, CHEN Jing, YAN Haiyang, et al. The Relationship Between XRCC1 TYMS MTHFR Gene Polymorphisms and the Efficacy of Adjuvant Chemotherapy After Colon Cancer Surgery. HeBei Med, 2022, 28(5): 750-753.
2022, Vol. 28 
冀公网安备13080202000677号